Use of CircRAB3IP in preparation of a drug for promoting angiogenesis

By overexpressing circRAB3IP in cardiomyocytes to promote angiogenesis, the problem of insufficient capillary density in pathological myocardial hypertrophy was addressed, resulting in improved cardiac function and reduced myocardial fibrosis, thus providing a new treatment method for cardiac remodeling.

CN116492364BActive Publication Date: 2025-10-21ZHONGSHAN HOSPITAL FUDAN UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202310558544.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-17
Publication Date
2025-10-21
Estimated Expiration
2043-05-17

AI Technical Summary

Technical Problem

In the existing technology, insufficient capillary density during pathological myocardial hypertrophy leads to insufficient supply of oxygen and nutrients, which in turn causes myocardial cell death or fibrosis. There is a lack of effective angiogenesis regulation methods to delay heart failure.

Method used

circRAB3IP was used to promote angiogenesis in drug preparation. By overexpressing circRAB3IP in cardiomyocytes, the expression of angiogenic factors was enhanced, microvascular angiogenesis was promoted, and cardiac dysfunction was improved.

Benefits of technology

circRAB3IP significantly promotes angiogenesis, slows myocardial fibrosis, improves cardiac function, delays cardiac remodeling, and provides a therapeutic target for hypertensive cardiac remodeling.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present application relates to the application of CircRAB3IP in the preparation of a drug for promoting angiogenesis, and belongs to the technical field of biological medicine; the present application provides the application of CircRAB3IP in the preparation of a drug for preventing or treating heart failure; in the preparation of a drug for promoting angiogenesis; in the preparation of a heart failure prognosis diagnosis kit; and in the preparation of a myocardial hypertrophy prognosis diagnosis kit; the present application proves through in-vivo and in-vitro experiments that circRAB3IP can promote angiogenesis, and can effectively improve heart function disorder caused by high blood pressure mechanical stress, slow down cardiac remodeling, myocardial fibrosis, and reduce cardiac inflammation. The present application provides a new target and theoretical basis for the treatment of hypertensive cardiac remodeling.
Need to check novelty before this filing date? Find Prior Art